Reports Q3 revenue $3.9M, consensus $5.88M. The company said, “Our third quarter results reflect typical summer seasonality and macroeconomic conditions. While economic challenges continue to affect many dermatologists, we used our strong cash position to build inventory in order to be able to quickly address demand as our customers adjust to higher inflation and interest rates. Utilization of SRT to treat non-melanoma skin cancer continues to increase, driven by favorable reimbursement, an aging population and clinical results that are as good, if not better than, Mohs surgery. The fourth quarter is off to a good start with participation in the Fall Clinical dermatology conference and the American Association of Radiation Oncology annual meeting, both in October. The attention our products received at these important trade shows bolsters our optimism for the future as we enter the year’s strongest sales quarter with new features to improve the use of SRT in dermatology and oncology practice settings,” he added. “For example, our HIPAA-compliant Sentinel IT software allows customers to document and store patient data for clinical, billing and asset-management purposes, and also allows us to track utilization.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SRTS:
- Sensus Healthcare Reports Third Quarter 2023 Financial Results
- SRTS Upcoming Earnings Report: What to Expect?
- Sensus Healthcare to Host Third Quarter 2023 Financial Results and Business Update Conference Call on Thursday, November 9, 2023
- Sensus Healthcare to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference
- Sensus Healthcare sells superficial radiotherapy system to Cape Cod Hospital